The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Naji Abumrad, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00568620
First received: December 4, 2007
Last updated: June 17, 2013
Last verified: June 2013
  Purpose

In parallel with the increasing prevalence of obesity worldwide, type 2 diabetes mellitus (T2DM) has reached epidemic proportions. Despite a multitude of available therapies, only bariatric surgery (e.g., roux-en-Y gastric bypass (GBP)) has proven to be an effective long term treatment modality for morbid obesity. Moreover, the majority of T2DM patients who undergo GBP experience normalization of their blood glucose and are able to discontinue their anti-diabetes medications soon after the procedure. The insulin resistant state commonly seen in non-diabetic obese subjects also improves after GBP. Evidence from recent animal studies suggests that the rapid return to euglycemia seen in T2DM patients after GBP might in part result from excluding the duodenum from the flow of nutrients. With the use of enteral feeding tubes, we hope to better understand the factors in the human gut that may predispose obese individuals to the development of insulin resistance and T2DM.


Condition Intervention
Insulin Resistance and Type 2 Diabetes
Procedure: Placement of nasogastric feeding tube
Procedure: Nasojejunal feeding tube

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Insulin sensitivity [ Time Frame: 3 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incretin effect [ Time Frame: 3 days ] [ Designated as safety issue: No ]

Enrollment: 19
Study Start Date: May 2008
Study Completion Date: December 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1: Nasogastric feeding tube Procedure: Placement of nasogastric feeding tube

Glucose tolerance test via nasogastric feeding tube

50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3

Experimental: 2: Placement of nasojejunal feeding tube Procedure: Nasojejunal feeding tube

Glucose tolerance test via nasojejunal feeding tube

50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3


  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Inclusion criteria for lean, healthy control subjects:

  1. Fasting plasma glucose (FPG) < 100
  2. Age 18 to 55
  3. BMI 18.5 to 24.9 kg/m2
  4. Stable weight for prior 3 months

Inclusion criteria for prediabetic individuals:

  1. Based on American Diabetes Association criteria of FPG > 100 and <126
  2. Age 18 to 55
  3. BMI 35 to 60 kg/m2
  4. Stable weight for prior 3 months

Inclusion criteria for diabetic individuals:

  1. Diagnosis of type 2 diabetes mellitus (T2DM) for < 5 years
  2. Hemoglobin A1c < 8%
  3. Age 18 to 55
  4. BMI 35 to 60 kg/m2
  5. Stable weight for prior 3 months

Exclusion Criteria:

Exclusion criteria for all study subjects:

  1. Use of any of the following medications: Thiazolidinediones, dipeptidyl-peptidase IV (DPP-IV) inhibitors (e.g., sitagliptin), GLP-1 analogs (e.g., exenatide).
  2. Subjects with T2DM who are unable to maintain adequate glycemic control (i.e., having a fasting blood glucose that exceeds 250mg/dL on two consecutive tests) while temporarily discontinuing their oral diabetes medications for the study and in whom the study physician determines insulin therapy would not be appropriate.
  3. Females with a positive pregnancy test

5. Prior gastric, duodenal, proximal jejunal surgery or pancreas resection 6. Known malabsorptive disorder 7. History of cancer in past 5 years 8. Renal insufficiency defined by serum creatinine > 1.5 mg/dl 9. Hepatic enzyme elevations of greater than twice the upper limits of normal 10. Current use of warfarin or clopidogrel 11. Intercurrent infections 12. Contraindication to nasogastric or nasojejunal feeding tube (e.g., deviated nasal septum, prior upper gastrointestinal bleed, or history of easy bleeding) 13. Residence outside the greater Nashville, TN area

  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Naji Abumrad, Chairman, Department of Surgery, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00568620     History of Changes
Other Study ID Numbers: IRB#070770, R01DK070860, GCRC #1710
Study First Received: December 4, 2007
Last Updated: June 17, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperinsulinism

ClinicalTrials.gov processed this record on April 15, 2014